nach oben

Erschienen in:

01.04.2014 | Original Article

Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma

verfasst von: Akimasa Hayashi, Teppei Morikawa, Taketo Kawai, Haruki Kume, Shumpei Ishikawa, Yukio Homma, Masashi Fukayama

Erschienen in: Virchows Archiv | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Evidence suggests that overexpression of enhancer of zeste homologue 2 (EZH2) is associated with aggressive behavior in various cancers. However, the clinical, pathological, and prognostic associations of EZH2 expression in the upper urinary tract carcinoma have not been reported. This study aimed to investigate the significance of EZH2 expression in the upper urinary tract carcinoma by immunohistochemical analysis using a tissue microarray. High EZH2 expression was observed in 94 of 171 (55 %) cases and was significantly associated with several adverse prognostic factors, including sessile architecture, high histological grade, presence of lymphovascular invasion, concomitant carcinoma in situ, higher tumor stage, and higher Ki-67 expression (all P < 0.01). EZH2 expression status in primary and metastatic lesions was concordant in all 13 cases examined. Survival analyses were performed using the Kaplan–Meier method and multivariate Cox proportional hazards regression models. High EZH2 expression was significantly associated with a shorter metastasis-free survival (log-rank P = 0.005; multivariate hazard ratio, 1.85; 95 % confidence interval, 0.93–3.71) and cancer-specific survival (log-rank P = 0.006; multivariate hazard ratio, 3.08; 95 % confidence interval, 1.30–7.32) after nephroureterectomy. Our results suggest that EZH2 may serve as a novel prognostic biomarker and a potential therapeutic target in upper urinary tract carcinoma.

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63:1059–1071PubMedCrossRef

Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C (2011) Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol 3:69–80. doi:10.1177/1756287211403349 PubMedCrossRefPubMedCentral

Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, Tanaka T, Masumori N, Sato N, Tsukamoto T (2013) Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch 462:101–107PubMedCrossRef

Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martinez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61:818–825. doi:10.1016/j.eururo.2012.01.021 PubMedCrossRef

Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF (2011) Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 8:440–447. doi:10.1038/nrurol.2011.96 PubMedCrossRef

Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114. doi:10.1016/j.eururo.2012.02.030 PubMedCrossRef

Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153:17–37. doi:10.1016/j.cell.2013.03.002 PubMedCrossRef

Shen H, Laird PW (2013) Interplay between the cancer genome and epigenome. Cell 153:38–55. doi:10.1016/j.cell.2013.03.008 PubMedCrossRefPubMedCentral

Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–856PubMedCrossRef

10.

Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606–11611PubMedCrossRefPubMedCentral

11.

Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29PubMedCrossRef

12.

Grignon DJ (2009) The current classification of urothelial neoplasms. Mod Pathol 22(Suppl 2):S60–S69. doi:10.1038/modpathol.2008.235 PubMedCrossRef

13.

Morikawa T, Maeda D, Kume H, Homma Y, Fukayama M (2010) Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 57:885–892PubMedCrossRef

14.

Raaphorst FM, van Kemenade FJ, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ (2000) Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 164:1–4PubMedCrossRef

15.

Hinz S, Magheli A, Weikert S, Schulze W, Krause H, Schrader M, Miller K, Kempkensteffen C (2010) Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. World J Urol 28:631–635PubMedCrossRef

16.

Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M, Aburatani H (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13:5703–5709PubMedCrossRef

17.

Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97:484–491PubMedCrossRef

18.

Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122:595–602PubMedCrossRef

19.

Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K, Ito H (2009) High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 45:39–46PubMedCrossRef

20.

Kamijima S, Tobe T, Suyama T, Ueda T, Igarashi T, Ichikawa T, Ito H (2005) The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 12:941–947. doi:10.1111/j.1442-2042.2005.01159.x PubMedCrossRef

21.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268–273PubMedCrossRef

22.

Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12:1168–1174PubMedCrossRef

23.

Chowdhury GM, Kojima K, Kanayama H, Tsuji M, Kurokawa Y, Kagawa S (1996) The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer 78:827–833PubMedCrossRef

24.

Jeon HG, Jeong IG, Bae J, Lee JW, Won JK, Paik JH, Kim HH, Lee SE, Lee E (2010) Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 76(513):e512–e517

25.

Joung JY, Yang SO, Jeong IG, Han KS, Seo HK, Chung J, Park WS, Lee GK, Lee KH (2008) Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors. Urol Int 81:306–311. doi:10.1159/000151409 PubMedCrossRef

26.

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629PubMedCrossRef

27.

Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661–668PubMedCrossRef

28.

Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M (2005) Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31:376–380PubMedCrossRef

29.

Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, Field HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, Ponder BA, Nakamura Y, Hamamoto R (2011) Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102:1298–1305PubMedCrossRef

30.

Wagener N, Macher-Goeppinger S, Pritsch M, Husing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M (2010) Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10:524PubMedCrossRefPubMedCentral

31.

Wan L, Li X, Shen H, Bai X (2013) Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics. Clin Transl Oncol 15:132–138PubMedCrossRef

32.

Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, Krause H (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16:349–353PubMed

33.

Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E (2005) Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75:252–257PubMedCrossRef

34.

Hinz S, Kempkensteffen C, Christoph F, Hoffmann M, Krause H, Schrader M, Schostak M, Miller K, Weikert S (2008) Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J Cancer Res Clin Oncol 134:331–336PubMedCrossRef

35.

Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML (2012) Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol 30:428–433PubMedCrossRef

36.

Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernandez MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618. doi:10.1200/JCO.2008.17.2361 PubMedCrossRefPubMedCentral

37.

Xiao Y (2011) Enhancer of zeste homolog 2: a potential target for tumor therapy. Int J Biochem Cell Biol 43:474–477PubMedCrossRef

38.

Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, Danesi R (2012) EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 31:753–761PubMedCrossRef

39.

McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–112PubMedCrossRef

40.

Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547–556PubMedCrossRef

41.

Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF (2007) Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46:200–208PubMedCrossRef

42.

Wagener N, Holland D, Bulkescher J, Crnkovic-Mertens I, Hoppe-Seyler K, Zentgraf H, Pritsch M, Buse S, Pfitzenmaier J, Haferkamp A, Hohenfellner M, Hoppe-Seyler F (2008) The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 123:1545–1550PubMedCrossRef

43.

Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Durst M, Hoppe-Seyler F (2008) Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res 68:9964–9972PubMedCrossRef

44.

Zhang YB, Niu HT, Chang JW, Dong GL, Ma XB (2011) EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Eur J Cancer Care (Engl) 20:106–112CrossRef

45.

Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 102:12177–12182. doi:10.1073/pnas.0501753102 PubMedCrossRefPubMedCentral

46.

Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16:286–294. doi:10.1038/nm.2100 PubMedCrossRefPubMedCentral

47.

Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B (2004) Focus on bladder cancer. Cancer Cell 6:111–116. doi:10.1016/j.ccr.2004.08.002 PubMedCrossRef

Titel: Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma
verfasst von: Akimasa Hayashi
Teppei Morikawa
Taketo Kawai
Haruki Kume
Shumpei Ishikawa
Yukio Homma
Masashi Fukayama
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 4/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1541-6

Springer Medizin

Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma

Reproducibility of histopathologic tumor grading in penile cancer—results of a European project

In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor

Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study

Lipomatous tumors of the anterior mediastinum with muscle differentiation: a clinicopathological and immunohistochemical study of three cases

Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie